Figure 4.

Efficient inhibition of SVV infection via the engineered CRISPR-Cas13d system. (A) HEK-293T cells were cotransfected with Cas13d and the indicated crRNAs plasmid, the cells viability at 24 hpt or 48 hpt was determined. (B) HEK-293T cells were cotransfected with Cas13d and the indicated crRNAs plasmid. Twenty-four hours later, the cells were infected with SVV (at an MOI of 0.01), and viral titers in the cell culture supernatants at 24 hpi or (D) at 48 hpi were determined. (C) The percentage reduction of virus titers was detected in the crRNA groups (#1, #2, #3, and #4) relative to the crRNA control group at 24 hpi or (E) at 48 hpi. (F) HEK-293T cells were cotransfected with Cas13d and the indicated crRNAs plasmid or crRNAs pool. Twenty-four hours later, the cells were infected with SVV (at an MOI of 1), and viral titers in the cell culture supernatants at 48 hpi were determined. (G) The percentage reduction of virus titers was detected in the crRNA groups (#1, #2, #3, #4, and mixed pool) relative to the crRNA control group at 48 hpi. Error bars represent the SD; ^*p < 0.05, ^***p < 0.001.